Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | FPR2 | P25090 | 4/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
| ▸ | CTSS | P25774 | 4/20 | 0.37 |
| ▸ | ELANE | P08246 | 2/20 | 0.35 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.35 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6061692 | 0.85 | CTSS (0.41) | CTSSELANE | |
| SCHEMBL7048374 | 0.77 | POLB (0.38) | POLBFPR2EPHX2BDKRB2ADRB2 | |
| SCHEMBL7045911 | 0.76 | EPHX2 (0.47) | EPHX2CTSSELANEKDM4E | |
| SCHEMBL6463639 | 0.74 | PSMB5 (0.37) | POLBFPR2EPHX2BDKRB2 | |
| SCHEMBL6466351 | 0.72 | FAAH (0.38) | CTSSELANE | |
| SCHEMBL7044254 | 0.72 | KMT2A (0.42) | CTSS | |
| SCHEMBL7043177 | 0.71 | FPR2 (0.53) | FPR2CTSS | |
| SCHEMBL7045315 | 0.71 | KMT2A (0.39) | — | |
| SCHEMBL6463422 | 0.71 | FAAH (0.41) | CTSS | |
| SCHEMBL6461911 | 0.70 | FAAH (0.42) | CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | US | disclosed |
| US-6576630-B1 | Alkanoyl substituted benzooxazoles or naphthooxazoles | AXYS PHARMACEUTICALS, INC. | 2003-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | SERPINB1, CTRL, CTSZ | POLB 3957/4885FPR2 2099/4885EPHX2 696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.